Liontrust Investment Partners LLP Grows Stock Holdings in Eli Lilly and Company $LLY

Liontrust Investment Partners LLP lifted its position in Eli Lilly and Company (NYSE:LLY) by 74.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 55,060 shares of the company’s stock after buying an additional 23,501 shares during the period. Liontrust Investment Partners LLP’s holdings in Eli Lilly and Company were worth $42,921,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hohimer Wealth Management LLC boosted its stake in Eli Lilly and Company by 5.3% in the second quarter. Hohimer Wealth Management LLC now owns 1,519 shares of the company’s stock valued at $1,184,000 after acquiring an additional 76 shares in the last quarter. Brick & Kyle Associates lifted its holdings in shares of Eli Lilly and Company by 63.8% during the 2nd quarter. Brick & Kyle Associates now owns 4,364 shares of the company’s stock valued at $3,382,000 after purchasing an additional 1,700 shares during the last quarter. Old North State Trust LLC boosted its position in shares of Eli Lilly and Company by 3.8% in the 2nd quarter. Old North State Trust LLC now owns 7,394 shares of the company’s stock worth $5,764,000 after purchasing an additional 269 shares in the last quarter. Tactive Advisors LLC purchased a new position in Eli Lilly and Company during the 2nd quarter worth $662,000. Finally, Kestra Investment Management LLC increased its position in Eli Lilly and Company by 8.0% during the 2nd quarter. Kestra Investment Management LLC now owns 3,478 shares of the company’s stock valued at $2,711,000 after buying an additional 257 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $1,027.68 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The firm has a 50 day moving average of $939.47 and a two-hundred day moving average of $819.64. The firm has a market capitalization of $971.55 billion, a PE ratio of 50.28, a P/E/G ratio of 1.14 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the firm earned $1.18 EPS. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Wells Fargo & Company raised their price target on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Wednesday. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. UBS Group raised their price target on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,121.90.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.